Terms: = Ovarian cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Clinical Outcome
4 results:
1. The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways.
Wang L; Chen Y; Li H; Xu Q; Liu R
Fundam Clin Pharmacol; 2022 Feb; 36(1):81-88. PubMed ID: 34212421
[TBL] [Abstract] [Full Text] [Related]
2. Salvage surgery due to bowel obstruction in advanced or relapsed ovarian cancer resulting in short bowel syndrome and long-life total parenteral nutrition: surgical and clinical outcome.
Fotopoulou C; Braicu EI; Kwee SL; Kuhberg M; Richter R; Pietzner K; Feldheiser A; Bahra M; Schmidt SC; Sehouli J
Int J Gynecol Cancer; 2013 Oct; 23(8):1495-500. PubMed ID: 24189059
[TBL] [Abstract] [Full Text] [Related]
3. outcome after ovarian/adnexal metastectomy in metastatic colorectal carcinoma.
Rayson D; Bouttell E; Whiston F; Stitt L
J Surg Oncol; 2000 Nov; 75(3):186-92. PubMed ID: 11088050
[TBL] [Abstract] [Full Text] [Related]
4. clinical usefulness of serum sialyl SSEA-1 antigen levels in patients with epithelial ovarian cancer. Comparative effectiveness of sialyl SSEA-1 and CA 125.
Kobayashi H; Kawashima Y
Gynecol Obstet Invest; 1990; 30(1):52-8. PubMed ID: 1977666
[TBL] [Abstract] [Full Text] [Related]
